Corcept Faces New Competitive Pressure as Genmab’s Rina-S Shows Broad Benefit in Platinum-Resistant Ovarian Cancer
Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.
Rina-S shows significant PFS and OS gains in platinum-resistant ovarian cancer, challenging Corcept’s Lifyorli position.
A patient with highly active relapsing MS died 44 days after receiving BMS’s experimental CD19 CAR-T therapy zola-cel in an early-stage trial.
Bolt Biotherapeutics merges with Prana Therapies in a $120 million deal to advance PRA-216 through Phase 2 trials in asthma, COPD, and atopic dermatitis.
Shares of Aardvark Therapeutics dropped after limited HERO data showed only temporary benefit for ARD-101 in Prader-Willi syndrome, delaying restart to 2027.
BDR Pharmaceuticals has sued the FDA over its decision to extend VOQUEZNA’s new chemical entity exclusivity through May 2032 under the GAIN Act.
Updated Phase 1/2 data at ESMO showed 82% ORR and 88% 9-month PFS with vopimetostat plus daraxonrasib in previously treated MTAP-deleted RAS-mutant PDAC.